198 related articles for article (PubMed ID: 23348700)
1. A novel antitumor activity of deguelin targeting the insulin-like growth factor (IGF) receptor pathway via up-regulation of IGF-binding protein-3 expression in breast cancer.
Suh YA; Kim JH; Sung MA; Boo HJ; Yun HJ; Lee SH; Lee HJ; Min HY; Suh YG; Kim KW; Lee HY
Cancer Lett; 2013 May; 332(1):102-9. PubMed ID: 23348700
[TBL] [Abstract][Full Text] [Related]
2. Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells.
Mehta R; Katta H; Alimirah F; Patel R; Murillo G; Peng X; Muzzio M; Mehta RG
PLoS One; 2013; 8(6):e65113. PubMed ID: 23762292
[TBL] [Abstract][Full Text] [Related]
3. Triptolide inhibits human breast cancer MCF-7 cell growth via downregulation of the ERα-mediated signaling pathway.
Li H; Pan GF; Jiang ZZ; Yang J; Sun LX; Zhang LY
Acta Pharmacol Sin; 2015 May; 36(5):606-13. PubMed ID: 25864647
[TBL] [Abstract][Full Text] [Related]
4. Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo.
Gründker C; Föst C; Fister S; Nolte N; Günthert AR; Emons G
Breast Cancer Res; 2010; 12(4):R49. PubMed ID: 20630060
[TBL] [Abstract][Full Text] [Related]
5. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy.
Davison Z; de Blacquière GE; Westley BR; May FE
Neoplasia; 2011 Jun; 13(6):504-15. PubMed ID: 21677874
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
Martin JL; de Silva HC; Lin MZ; Scott CD; Baxter RC
Mol Cancer Ther; 2014 Feb; 13(2):316-28. PubMed ID: 24337110
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells.
Liu T; Yacoub R; Taliaferro-Smith LD; Sun SY; Graham TR; Dolan R; Lobo C; Tighiouart M; Yang L; Adams A; O'Regan RM
Mol Cancer Ther; 2011 Aug; 10(8):1460-9. PubMed ID: 21690228
[TBL] [Abstract][Full Text] [Related]
9. Flaxseed oil reduces the growth of human breast tumors (MCF-7) at high levels of circulating estrogen.
Truan JS; Chen JM; Thompson LU
Mol Nutr Food Res; 2010 Oct; 54(10):1414-21. PubMed ID: 20425756
[TBL] [Abstract][Full Text] [Related]
10. Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer.
Robles AJ; Cai S; Cichewicz RH; Mooberry SL
Breast Cancer Res Treat; 2016 Jun; 157(3):475-88. PubMed ID: 27255535
[TBL] [Abstract][Full Text] [Related]
11. FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo.
Sharpe R; Pearson A; Herrera-Abreu MT; Johnson D; Mackay A; Welti JC; Natrajan R; Reynolds AR; Reis-Filho JS; Ashworth A; Turner NC
Clin Cancer Res; 2011 Aug; 17(16):5275-86. PubMed ID: 21712446
[TBL] [Abstract][Full Text] [Related]
12. Specific targeting of insulin-like growth factor 1 receptor signaling in human estrogen dependent breast cancer cell by a novel tyrosine-based benzoxazepine derivative.
Chakravarti B; Siddiqui JA; Dwivedi SK; Deshpande S; Samanta K; Bhatta RS; Panda G; Prabhakar YS; Konwar R; Sanyal S; Chattopadhyay N
Mol Cell Endocrinol; 2011 May; 338(1-2):68-78. PubMed ID: 21457754
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer amelioration by Butea monosperma in-vitro and in-vivo.
Karia P; Patel KV; Rathod SSP
J Ethnopharmacol; 2018 May; 217():54-62. PubMed ID: 29366766
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor-binding protein 3 induces caspase-dependent apoptosis through a death receptor-mediated pathway in MCF-7 human breast cancer cells.
Kim HS; Ingermann AR; Tsubaki J; Twigg SM; Walker GE; Oh Y
Cancer Res; 2004 Mar; 64(6):2229-37. PubMed ID: 15026367
[TBL] [Abstract][Full Text] [Related]
15. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
[TBL] [Abstract][Full Text] [Related]
16. Deguelin suppresses non-small cell lung cancer by inhibiting EGFR signaling and promoting GSK3β/FBW7-mediated Mcl-1 destabilization.
Gao F; Yu X; Li M; Zhou L; Liu W; Li W; Liu H
Cell Death Dis; 2020 Feb; 11(2):143. PubMed ID: 32081857
[TBL] [Abstract][Full Text] [Related]
17. Deguelin inhibits growth of breast cancer cells by modulating the expression of key members of the Wnt signaling pathway.
Murillo G; Peng X; Torres KE; Mehta RG
Cancer Prev Res (Phila); 2009 Nov; 2(11):942-50. PubMed ID: 19861542
[TBL] [Abstract][Full Text] [Related]
18. Deguelin induces apoptosis by targeting both EGFR-Akt and IGF1R-Akt pathways in head and neck squamous cell cancer cell lines.
Baba Y; Fujii M; Maeda T; Suzuki A; Yuzawa S; Kato Y
Biomed Res Int; 2015; 2015():657179. PubMed ID: 26075254
[TBL] [Abstract][Full Text] [Related]
19. Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer.
Iida M; Tsuboi K; Niwa T; Ishida T; Hayashi SI
Breast Cancer; 2019 May; 26(3):272-281. PubMed ID: 30328006
[TBL] [Abstract][Full Text] [Related]
20. The novel camptothecin derivative, CPT211, induces cell cycle arrest and apoptosis in models of human breast cancer.
Chiu CF; Lin YQ; Park JM; Chen YC; Hung SW; Chiu CC; Chang CF
Biomed Pharmacother; 2020 Aug; 128():110309. PubMed ID: 32505820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
